DMAC Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
10.5M
+13.8%
9.2M
+2.0%
9.0M
+12.8%
8.0M
-1.7%
8.1M
R&D
8.0M
+19.2%
6.7M
+4.1%
6.4M
+10.6%
5.8M
+2.9%
5.7M
SG&A
2.5M
-0.8%
2.5M
-3.2%
2.6M
+18.8%
2.2M
-12.2%
2.5M
Operating Income
-10482000
-13.8%
-9213000
-2.0%
-9033000
-12.8%
-8007000
+1.7%
-8144000
EBITDA
-10471000
-13.8%
-9202000
-2.1%
-9015000
-12.6%
-8004000
+1.6%
-8133000
Net Income
-10042000
-14.9%
-8740000
-1.4%
-8620000
-12.0%
-7699000
+0.1%
-7707000
EPS (Basic)
$-0.19
-11.8%
$-0.17
+0.0%
$-0.17
+5.6%
$-0.18
+0.0%
$-0.18
EPS (Diluted)
$-0.19
-11.8%
$-0.17
+0.0%
$-0.17
+5.6%
$-0.18
+0.0%
$-0.18
Shares (Diluted)
53.8M
+2.5%
52.5M
+5.8%
49.6M
+15.5%
43.0M
+0.3%
42.8M
DiaMedica Therapeutics (DMAC) โ€” Financials